300725 药石科技
交易中 07-24 10:25:03
资讯
新帖
简况
7月17日药石科技跌11.77%，信澳优享生活混合A基金重仓该股
证券之星 · 07-17
7月17日药石科技跌11.77%，信澳优享生活混合A基金重仓该股
7月14日药石科技创60日新高，信澳优享生活混合A基金重仓该股
证券之星 · 07-14
7月14日药石科技创60日新高，信澳优享生活混合A基金重仓该股
开源证券：给予药石科技买入评级
证券之星 · 07-06
开源证券：给予药石科技买入评级
药石科技（300725）披露调整2026年度日常关联交易预计公告，7月3日股价上涨1.47%
证券之星 · 07-03
药石科技（300725）披露调整2026年度日常关联交易预计公告，7月3日股价上涨1.47%
6月29日药石科技涨7.97%，信澳优享生活混合A基金重仓该股
证券之星 · 06-29
6月29日药石科技涨7.97%，信澳优享生活混合A基金重仓该股
股市必读：药石科技（300725）6月24日董秘有最新回复
证券之星 · 06-25
股市必读：药石科技（300725）6月24日董秘有最新回复
药石科技：公司通过深化全球布局、拓展多元化客户网络以及强化技术领先优势，积极应对外部环境的不确定性
证券之星 · 06-13
药石科技：公司通过深化全球布局、拓展多元化客户网络以及强化技术领先优势，积极应对外部环境的不确定性
药石科技：IPO募投项目及可转债募投项目均已实施完成并产生收益
证券之星 · 06-13
药石科技：IPO募投项目及可转债募投项目均已实施完成并产生收益
药石科技：聚焦成为“赋能下一代疗法的绿色智能化学引擎”
证券之星 · 06-13
药石科技：聚焦成为“赋能下一代疗法的绿色智能化学引擎”
药石科技：截止2026年6月10日，公司股东人数40,311名
证券之星 · 06-13
药石科技：截止2026年6月10日，公司股东人数40,311名
药石科技：截至2026年5月20日，公司股东人数42,369名
证券之星 · 06-05
药石科技：截至2026年5月20日，公司股东人数42,369名
药石科技：聚焦“赋能下一代疗法”
证券之星 · 06-05
药石科技：聚焦“赋能下一代疗法”
药石科技：公司主营业务为提供从药物发现到商业化生产的全面一体化CRDMO服务
证券之星 · 06-03
药石科技：公司主营业务为提供从药物发现到商业化生产的全面一体化CRDMO服务
药石科技：截至2026年第一季度末，公司在手订单金额同比增长超过20%
证券之星 · 06-03
药石科技：截至2026年第一季度末，公司在手订单金额同比增长超过20%
药石科技：南京药石“新分子药物研发平台项目”首期预计于2026年第三季度投入使用
证券之星 · 05-25
药石科技：南京药石“新分子药物研发平台项目”首期预计于2026年第三季度投入使用
股市必读：药石科技（300725）5月22日董秘有最新回复
证券之星 · 05-25
股市必读：药石科技（300725）5月22日董秘有最新回复
药石科技：仲丁基锂连续流工艺成功应用
证券之星 · 05-23
药石科技：仲丁基锂连续流工艺成功应用
5月14日药石科技跌5.59%，信澳优享生活混合A基金重仓该股
证券之星 · 05-14
5月14日药石科技跌5.59%，信澳优享生活混合A基金重仓该股
药石科技：公司在高活性试剂连续流工艺等领域的技术积累
证券之星 · 05-07
药石科技：公司在高活性试剂连续流工艺等领域的技术积累
股市必读：药石科技（300725）5月6日披露最新机构调研信息
证券之星 · 05-07
股市必读：药石科技（300725）5月6日披露最新机构调研信息
加载更多
公司概况
公司名称：
南京药石科技股份有限公司
所属行业：
化学原料和化学制品制造业
上市日期：
2017-11-10
主营业务：
南京药石科技股份有限公司的主营业务是为小分子药物研发领域提供创新型化学产品和相关技术服务。公司的主要产品是药物研究阶段的产品和服务、药物开发及商业化阶段的产品和服务。公司在标普全球企业可持续发展评估（S＆PCSA）中得分58分，位列行业前列，入选《可持续发展年鉴（中国版）2026》并荣获“制药行业最佳进步企业”称号；在CDP（全球环境信息研究中心）气候变化与水安全问卷评级中均获得B级。此外，公司再度荣获WindESGAA评级，总分在CRDMO行业中位居前列，其中环境维度获得满分。
发行价格：
11.32
{"stockData":{"symbol":"300725","market":"SZ","secType":"STK","nameCN":"药石科技","latestPrice":38.76,"timestamp":1784859903000,"preClose":38.8,"halted":0,"volume":6819695,"delay":0,"changeRate":-0.001,"floatShares":202999999,"shares":234000000,"eps":0.8419,"marketStatus":"交易中","change":-0.04,"latestTime":"07-24 10:25:03","open":38.4,"high":39.45,"low":37.82,"amount":264000000,"amplitude":0.042,"askPrice":38.76,"askSize":7,"bidPrice":38.74,"bidSize":24,"shortable":0,"etf":0,"ttmEps":0.8419,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1784863800000},"marketStatusCode":2,"adr":0,"adjPreClose":38.8,"symbolType":"stock","openAndCloseTimeList":[[1784856600000,1784863800000],[1784869200000,1784876400000]],"highLimit":42.68,"lowLimit":34.92,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":233807341,"isCdr":false,"pbRate":1.65,"roa":"--","peRate":46.038722,"roe":"0.83%","epsLYR":0.88,"committee":0.165746,"marketValue":9062000000,"turnoverRate":0.0336,"status":1,"floatMarketCap":7857000000},"requestUrl":"/m/hq/s/300725","defaultTab":"news","newsList":[{"id":"2652840674","title":"7月17日药石科技跌11.77%，信澳优享生活混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652840674","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652840674?lang=zh_cn&edition=full","pubTime":"2026-07-17 16:55","pubTimestamp":1784278542,"startTime":"0","endTime":"0","summary":"证券之星消息，7月17日药石科技跌11.77%，收盘报36.89元，换手率14.19%，成交量28.77万手，成交额11.05亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为信达澳亚基金的信澳优享生活混合A。信澳优享生活混合A目前规模为1.48亿元，最新净值1.0661，较上一交易日下跌4.68%，近一年下跌7.59%。信澳优享生活混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700030704.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01717","BK1553","BK0229","BK1597","BK1237","BK1500","300725"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651758221","title":"7月14日药石科技创60日新高，信澳优享生活混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651758221","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651758221?lang=zh_cn&edition=full","pubTime":"2026-07-14 16:32","pubTimestamp":1784017948,"startTime":"0","endTime":"0","summary":"证券之星消息，7月14日药石科技涨6.49%创60日新高，收盘报41.0元，换手率12.37%，成交量25.07万手，成交额10.0亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为信达澳亚基金的信澳优享生活混合A。信澳优享生活混合A目前规模为1.48亿元，最新净值1.0898，较上一交易日下跌6.12%，近一年下跌3.7%。信澳优享生活混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071400030888.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300725","BK0229","BK1500","BK1553","01717","BK1597","BK1237"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649499136","title":"开源证券：给予药石科技买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2649499136","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649499136?lang=zh_cn&edition=full","pubTime":"2026-07-06 15:15","pubTimestamp":1783322102,"startTime":"0","endTime":"0","summary":"开源证券股份有限公司余汝意近期对药石科技进行研究并发布了研究报告《公司信息更新报告：CRDMO转型稳步推进，盈利蓄力增长》，给予药石科技买入评级。最新盈利预测明细如下：该股最近90天内共有1家机构给出评级，买入评级1家。本文数据来源于开源证券股份有限公司，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070600014592.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300725","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648612056","title":"药石科技（300725）披露调整2026年度日常关联交易预计公告，7月3日股价上涨1.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648612056","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648612056?lang=zh_cn&edition=full","pubTime":"2026-07-03 22:33","pubTimestamp":1783089198,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘，药石科技报收于37.33元，较前一交易日上涨1.47%，最新总市值为87.28亿元。该股当日开盘37.28元，最高37.8元，最低36.28元，成交额达3.93亿元，换手率为5.23%。公司于近日披露《关于调整2026年度日常关联交易预计的公告》。关联交易定价参照市场价格协商确定，不存在损害公司及中小股东利益的情形。该事项在董事会审批权限内，无需提交股东大会审议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300045919.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300725","BK0229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647832218","title":"6月29日药石科技涨7.97%，信澳优享生活混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647832218","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647832218?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:52","pubTimestamp":1782723145,"startTime":"0","endTime":"0","summary":"证券之星消息，6月29日药石科技涨7.97%，收盘报36.18元，换手率7.53%，成交量15.26万手，成交额5.42亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为信达澳亚基金的信澳优享生活混合A。信澳优享生活混合A目前规模为1.48亿元，最新净值1.3234，较上一交易日下跌1.55%，近一年上涨21.8%。信澳优享生活混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900024868.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1597","BK1500","BK1237","300725","01717","BK0229","BK1553"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646179488","title":"股市必读：药石科技（300725）6月24日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2646179488","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646179488?lang=zh_cn&edition=full","pubTime":"2026-06-25 01:15","pubTimestamp":1782321313,"startTime":"0","endTime":"0","summary":"截至2026年6月24日收盘，药石科技报收于35.45元，上涨3.59%，换手率6.35%，成交量12.88万手，成交额4.54亿元。董秘最新回复投资者： 我作为一个药石的老股东，一个老化工人，看到不仅是药石在CDMO方面的实力，这方面主导药物开发。如有相关布局达到披露标准，将及时履行信息披露义务。2026年一季度，公司毛利率已回升至32.14%，在手订单同比增长超20%，经营呈现改善趋势。当日关注点交易信息汇总：6月24日主力资金净流入3025.79万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062500001196.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","300725"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643211219","title":"药石科技：公司通过深化全球布局、拓展多元化客户网络以及强化技术领先优势，积极应对外部环境的不确定性","url":"https://stock-news.laohu8.com/highlight/detail?id=2643211219","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643211219?lang=zh_cn&edition=full","pubTime":"2026-06-13 16:45","pubTimestamp":1781340307,"startTime":"0","endTime":"0","summary":"投资者提问：4.海外订单是公司核心收入来源，近期业绩波动是否受客户订单缩减影响？关于您提到的“近期业绩波动”，公司2026年第一季度报告已披露相关经营数据，目前经营情况正常，不存在应披露而未披露的重大信息。关于海外市场拓展，近期已经回复过您类似问题：公司通过深化全球布局、拓展多元化客户网络以及强化技术领先优势，积极应对外部环境的不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061300011031.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000973.SH","300725","BK0229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643112672","title":"药石科技：IPO募投项目及可转债募投项目均已实施完成并产生收益","url":"https://stock-news.laohu8.com/highlight/detail?id=2643112672","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643112672?lang=zh_cn&edition=full","pubTime":"2026-06-13 16:39","pubTimestamp":1781339945,"startTime":"0","endTime":"0","summary":"公司始终高度重视募集资金的使用效率和投资回报，并对募投项目实施持续跟踪与管理。IPO募投项目“创新药物分子砌块研发、工艺及中试平台建设项目”，以及可转债募投项目“收购浙江晖石46.07%股份”、“年产450吨小分子高端药物及关键中间体技改项目”、“补充流动性资金”，均已实施完成并产生收益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061300010699.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","300725"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643115632","title":"药石科技：聚焦成为“赋能下一代疗法的绿色智能化学引擎”","url":"https://stock-news.laohu8.com/highlight/detail?id=2643115632","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643115632?lang=zh_cn&edition=full","pubTime":"2026-06-13 14:36","pubTimestamp":1781332570,"startTime":"0","endTime":"0","summary":"证券之星消息，药石科技06月13日在投资者关系平台上答复投资者关心的问题。公司始终聚焦于成为“赋能下一代疗法的绿色智能化学引擎”，核心战略是为全球医药研发与生产提供全面一体化的CRDMO服务。目前，公司发展的基石仍是持续夯实医药CRDMO主业，巩固在该领域的技术领先性与客户粘性。如有其他业务布局达到法律、法规规定的披露标准，公司将及时履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061300007054.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300725","BK0229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643211568","title":"药石科技：截止2026年6月10日，公司股东人数40,311名","url":"https://stock-news.laohu8.com/highlight/detail?id=2643211568","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643211568?lang=zh_cn&edition=full","pubTime":"2026-06-13 14:36","pubTimestamp":1781332569,"startTime":"0","endTime":"0","summary":"证券之星消息，药石科技(300725)06月13日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，请问截止6月10日的股东户数？药石科技回复：截止2026年6月10日，公司股东人数40,311名。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061300007053.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","300725"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641092112","title":"药石科技：截至2026年5月20日，公司股东人数42,369名","url":"https://stock-news.laohu8.com/highlight/detail?id=2641092112","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641092112?lang=zh_cn&edition=full","pubTime":"2026-06-05 19:06","pubTimestamp":1780657567,"startTime":"0","endTime":"0","summary":"证券之星消息，药石科技(300725)06月05日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，近期股价持续调整，想了解筹码变化，请问截至2026年5月20日的股东户数是多少？机构户数是否有明显变化？谢谢！药石科技回复：投资者您好！截至2026年5月20日，公司股东人数42,369名；截至2026年5月29日，公司股东人数40,674名。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060500034556.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","300725"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641112799","title":"药石科技：聚焦“赋能下一代疗法”","url":"https://stock-news.laohu8.com/highlight/detail?id=2641112799","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641112799?lang=zh_cn&edition=full","pubTime":"2026-06-05 19:01","pubTimestamp":1780657260,"startTime":"0","endTime":"0","summary":"我们都是同路人，药石做大做强不光是公司高管，更是我们所有股民殷切期盼的。真心期盼，给个面子，重视一下药石科技回复：投资者您好！我们深切理解您对近期股价表现的关注，也感谢您作为“同路人”对公司长期发展的期盼。公司正积极把握行业机遇，聚焦“赋能下一代疗法”，通过深化绿色智能化学技术平台、优化全球布局、加强战略客户合作、拓展新兴治疗领域等一系列举措，持续巩固核心竞争力，夯实长期发展根基。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060500034389.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300725","BK0229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640970840","title":"药石科技：公司主营业务为提供从药物发现到商业化生产的全面一体化CRDMO服务","url":"https://stock-news.laohu8.com/highlight/detail?id=2640970840","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640970840?lang=zh_cn&edition=full","pubTime":"2026-06-03 17:00","pubTimestamp":1780477248,"startTime":"0","endTime":"0","summary":"国内创新药研发扩容能否完全对冲美国客户的政策风险？公司始终密切关注全球医药行业政策与监管环境的变化，并基于对行业趋势的研判，持续完善自身的风险管理体系。公司主营业务为提供从药物发现到商业化生产的全面一体化CRDMO服务，核心优势在于绿色与智能化学技术平台。目前，公司生产经营一切正常，具体业务与财务数据请以公司在巨潮资讯网披露的定期报告及公告为准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300034164.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300725","BK0229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640697087","title":"药石科技：截至2026年第一季度末，公司在手订单金额同比增长超过20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640697087","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640697087?lang=zh_cn&edition=full","pubTime":"2026-06-03 17:00","pubTimestamp":1780477247,"startTime":"0","endTime":"0","summary":"证券之星消息，药石科技06月03日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，2025年公司北美（美国）客户收入占比约46.8%，请问其中受美国BIOSECURE法案、Harris修正案潜在影响的订单占比多少？美国客户是否出现订单下滑、转移欧洲/亚洲产能的情况？目前，公司各项业务进展顺利。截至2026年第一季度末，公司在手订单金额同比增长超过20%，生产经营一切正常。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300034163.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","300725"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638539100","title":"药石科技：南京药石“新分子药物研发平台项目”首期预计于2026年第三季度投入使用","url":"https://stock-news.laohu8.com/highlight/detail?id=2638539100","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638539100?lang=zh_cn&edition=full","pubTime":"2026-05-25 17:18","pubTimestamp":1779700689,"startTime":"0","endTime":"0","summary":"经公司2026年第一次临时股东会审议批准，原募投项目浙江晖石“年产 155 吨创新药及关键中间体 CDMO 建设项目”已变更为南京药石 “新分子药物研发平台项目”与浙江晖石“化学合成新分子药物建设项目”。目前，两个新项目均按计划有序推进：南京药石 “新分子药物研发平台项目”首期预计于2026 年第三季度投入使用；浙江晖石“化学合成新分子药物建设项目”中的多肽中试车间预计于2026 年第二季度投入使用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500024007.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300725","BK0229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638330734","title":"股市必读：药石科技（300725）5月22日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2638330734","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638330734?lang=zh_cn&edition=full","pubTime":"2026-05-25 03:49","pubTimestamp":1779652149,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，药石科技报收于37.64元，上涨0.03%，换手率3.63%，成交量7.35万手，成交额2.76亿元。公司将持续关注客户需求，支持该项目的后续生产与供应。公司的法定信息披露渠道为巨潮资讯网及指定媒体，公司具体的经营数据、未来的业务拓展计划请关注公司发布的相关公告。当日关注点来自交易信息汇总：5月22日主力资金净流出269.25万元，游资资金净流入566.6万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500001575.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300725","BK0229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637219322","title":"药石科技：仲丁基锂连续流工艺成功应用","url":"https://stock-news.laohu8.com/highlight/detail?id=2637219322","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637219322?lang=zh_cn&edition=full","pubTime":"2026-05-23 20:39","pubTimestamp":1779539948,"startTime":"0","endTime":"0","summary":"证券之星消息，药石科技05月23日在投资者关系平台上答复投资者关心的问题。针对您集中提出的仲丁基锂连续流应用的多个问题，公司现统一回复如下：仲丁基锂连续流工艺的成功应用，旨在解决医药合成中高活性试剂的安全与规模化生产难题，目前主要服务于公司医药研发与生产业务的需求，以提升相关反应的安全性、效率与绿色化水平。以上内容为证券之星据公开信息整理，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052300014287.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300725","BK0229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635792738","title":"5月14日药石科技跌5.59%，信澳优享生活混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2635792738","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635792738?lang=zh_cn&edition=full","pubTime":"2026-05-14 16:40","pubTimestamp":1778748052,"startTime":"0","endTime":"0","summary":"证券之星消息，5月14日药石科技跌5.59%，收盘报37.68元，换手率5.59%，成交量11.33万手，成交额4.39亿元。融资融券方面近5日融资净流出1253.1万，融资余额减少；融券净流入1950.0，融券余额增加。重仓药石科技的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为信达澳亚基金的信澳优享生活混合A。该公募基金现任基金经理为杨珂。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400028835.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1500","BK1237","BK1553","BK1597","300725","BK0229","01717"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633113694","title":"药石科技：公司在高活性试剂连续流工艺等领域的技术积累","url":"https://stock-news.laohu8.com/highlight/detail?id=2633113694","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633113694?lang=zh_cn&edition=full","pubTime":"2026-05-07 15:48","pubTimestamp":1778140098,"startTime":"0","endTime":"0","summary":"证券之星消息，药石科技05月07日在投资者关系平台上答复投资者关心的问题。公司在高活性试剂连续流工艺等领域的技术积累，目前主要服务于医药研发与生产的需求，旨在提升反应的安全性、效率与绿色化水平。公司始终关注包括连续流、催化等在内的绿色化学技术的发展与应用前景，并将基于自身战略规划与核心能力，审慎评估相关技术的延伸可能性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050700021366.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","300725"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633623153","title":"股市必读：药石科技（300725）5月6日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2633623153","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633623153?lang=zh_cn&edition=full","pubTime":"2026-05-07 01:52","pubTimestamp":1778089931,"startTime":"0","endTime":"0","summary":"截至2026年5月6日收盘，药石科技报收于40.09元，上涨0.6%，换手率4.78%，成交量9.69万手，成交额3.88亿元。当日关注点来自交易信息汇总：5月6日主力资金净流出878.96万元，游资资金净流入1468.19万元。来自机构调研要点：南京学府路场地升级改造项目预计2026年第二季度投入使用，多个研发及中试项目将陆续投产。2025年第四季度营收同比微降0.95%，主因2024年同期特定订单集中交付；综合毛利率为30.48%，与年内其他季度基本持平。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050700001270.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","300725"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1784859905699,"stockEarnings":[{"period":"1week","weight":-0.072},{"period":"1month","weight":0.1338},{"period":"3month","weight":0.0255},{"period":"6month","weight":-0.1098},{"period":"1year","weight":-0.0525},{"period":"ytd","weight":0.0151}],"compareEarnings":[{"period":"1week","weight":-0.0015},{"period":"1month","weight":-0.0559},{"period":"3month","weight":-0.0498},{"period":"6month","weight":-0.0627},{"period":"1year","weight":0.0822},{"period":"ytd","weight":-0.0232}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"南京药石科技股份有限公司","boardCode":"AI0026","boardName":"化学原料和化学制品制造业","stockholders":"40311人(较上一季度减少0.89%)","perCapita":"5028股","listingDate":"2017-11-10","address":"江苏省南京市浦口区江北新区华盛路81号","registeredCapital":"23380万元","survey":" 南京药石科技股份有限公司的主营业务是为小分子药物研发领域提供创新型化学产品和相关技术服务。公司的主要产品是药物研究阶段的产品和服务、药物开发及商业化阶段的产品和服务。公司在标普全球企业可持续发展评估（S＆PCSA）中得分58分，位列行业前列，入选《可持续发展年鉴（中国版）2026》并荣获“制药行业最佳进步企业”称号；在CDP（全球环境信息研究中心）气候变化与水安全问卷评级中均获得B级。此外，公司再度荣获WindESGAA评级，总分在CRDMO行业中位居前列，其中环境维度获得满分。","listedPrice":11.32},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药石科技(300725)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药石科技(300725)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药石科技,300725,药石科技股票,药石科技股票老虎,药石科技股票老虎国际,药石科技行情,药石科技股票行情,药石科技股价,药石科技股市,药石科技股票价格,药石科技股票交易,药石科技股票购买,药石科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药石科技(300725)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药石科技(300725)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}